BTIG analyst Mark Massaro maintains $GeneDx Holdings (WGS.US)$ with a buy rating, and adjusts the target price from $45 to $95.
According to TipRanks data, the analyst has a success rate of 29.1% and a total average return of -10.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GeneDx Holdings (WGS.US)$'s main analysts recently are as follows:
GeneDx's considerable Q3 revenue surpassing expectations reflects the company's robust growth and effective execution. Although the company's valuation suggests a significant premium, this has been acknowledged. Moreover, the updated revenue forecasts for 2024-2026 indicate heightened expectations. The company's leadership is recognized for achieving one of the most remarkable and swift turnarounds in the sector.
GeneDx's recent Q3 report was characterized as 'another strong' performance, with an 18% revenue beat and an upward revision of the fiscal year revenue guidance. Significantly, the company achieved its profitability targets much sooner than anticipated.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
BTIG分析师Mark Massaro维持$GeneDx Holdings (WGS.US)$买入评级，并将目标价从45美元上调至95美元。
根据TipRanks数据显示，该分析师近一年总胜率为29.1%，总平均回报率为-10.4%。
此外，综合报道，$GeneDx Holdings (WGS.US)$近期主要分析师观点如下：
GenedX第三季度可观的收入超出预期，这反映了该公司的强劲增长和有效的执行。尽管该公司的估值表明溢价幅度很大，但这一点已得到承认。此外，最新的2024-2026年收入预测表明，预期有所提高。该公司的领导地位因实现该行业最引人注目和最迅速的转型之一而受到认可。
GenedX最近的第三季度报告被描述为 “又一次强劲” 的表现，收入超过18％，财年收入指引向上修正。值得注意的是，该公司实现盈利目标的速度比预期的要早得多。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
